DaShenLin Pharmaceutical is a pharmacy retail chain operating its own stores across multiple Chinese provinces, autonomous regions, and municipalities.
Dashenlin operates **8,615 franchised pharmacies** out of a total **19,791 pharmacies** as of September 2026, representing **43.5% of its network**. The company relies on franchising and acquisitions to expand, but analysts highlight the need for investors to evaluate **upfront costs, recurring franchise fees, and daily operating expenses** separately. Potential franchisees must weigh financial commitments against growth opportunities.
DaShenLin Pharmaceutical Group Co’s stock price increased by 9.99% in a single trading session. The company operates in the pharmaceutical sector, though no specific catalysts for the rise were detailed in the report.
Oct 2026Global Banking & Finance ReviewNews article
DaShenLin Pharmaceutical Group Co Ltd releases its Q3 2026 earnings results. Analysts track performance metrics amid market expectations for the biopharmaceutical company’s financial health and operational updates.
China’s retail pharmacy sector has shed over 20,000 stores in two years, with the total dropping to **656,000 in 2025** from **683,700 in 2024**. Shanghai-listed drugstore chains now show early signs of profit recovery after years of closures and declining earnings. The average pharmacy now serves **2,140 people**, up from **2,060** in 2024, as consolidation reshapes the market.